

Pharmacy Program Updates: Quarterly Pharmacy Changes Effective Jan. 1, 2023 – Part 1

Drug List Changes

Dispensing Limit Changes

Utilization Management Program Changes

Change in Benefit Coverage for Select High-Cost Products Pharmacy Reminders

- Implementation of New to Market Clinical Review Program for Select Prescription Drug Lists
- <u>New Proactive Utilization Management Approval Renewal Program:</u> <u>SmartRenewTM</u>
- Split Fill Program Category Expansion

IMPORTANT PHARMACY BENEFIT REMINDERS

Jan. 1, 2023 is the start of a new year and renewed or new health insurance benefits for most Blue Cross and Blue Shield of Oklahoma (BCBSOK) members. As you see your patients, please consider the following reminders:

- Members' benefits may be based on a new drug list when their plans renew in 2023. You can view a preview of the January drug lists on our <u>Member website</u>. The final lists will be available on both the member website and Pharmacy Program section of our Provider website closer to the January 1 effective date.
- Discuss your patients' benefits during an office visit or confirm their benefits by calling the number on their ID cards.
- Review the prescription drug list before prescribing medications.
- If your patients need a coverage exception or prior authorization request in order to take a medicine that may be excluded from coverage or included in a utilization management program, please visit the Prior Authorization/Step Therapy Programs section of our provider website at bcbsok.com/provider for the form and more information.

Some members' plans may experience changes to the pharmacy network starting Jan. 1, 2023. This includes plans that may have moved to a new pharmacy network or changes to pharmacies participating within the network. Based on claims data, members impacted by these changes will receive letters from BCBSOK to alert them.

Members who continue to fill prescriptions at a pharmacy no longer in their network will pay more. In most cases, no action is required on your part for any of these pharmacy network changes as members can easily transfer prescriptions to a nearby in-network pharmacy. If your office stores pharmacy information on your patient's records, you may want to ask which pharmacy is their preferred choice.

Treatment decisions are *always* between you and your patients. Coverage is subject to the terms and limits of your patients' benefit plans. Please advise them to review their benefit materials for details.

DRUG LIST CHANGES

Based on the availability of new prescription medications and Prime's National Pharmacy and Therapeutics Committee's review of changes in the pharmaceuticals market, some revisions (drugs still covered but moved to a higher out-of-pocket payment level) and/or exclusions (drugs no longer covered) will be made to the BCBSOK drug lists. Your patient(s) may ask you about therapeutic or lower cost alternatives if their medication is affected by one of these changes. Changes effective on or after Jan. 1, 2023 are outlined below.

The January Quarterly Pharmacy Changes Part 2 article with more recent coverage additions will be published closer to the Jan. 1 effective date.

Non-Preferred Brand ¹	Drug Class/ Condition Used For	Preferred Generic Alternative(s) ²	Preferred Brand Alternative(s) ^{1, 2}	
Basic, Multi-Ti	er Basic, Enhanced and	Multi-Tier Enhanced Drug	List Revisions	
NEXAVAR (sorafenib	Cancer	There is a generic equivalent available. Please talk		
tosylate tab 200 mg		to your doctor or pharmacist about other		
(base equivalent))		medication(s) available for your condition.		
VIMPAT (lacosamide	Seizures	There is a géneric equival		
oral solution 10 mg/ml)		to your doctor or pharmac		
3 3 7		medication(s) available for		
Drug ¹	Drug Class/Condition Used For	Generic Alternatives ^{1,2}	Brand Alternatives ^{1,2}	
Balanced	I, Performance and Perfo	ormance Select Drug List F	Revisions	
ALENDRONATE	Osteoporosis	alendronate tablets,		
SODIUM (alendronate		ibandronate tablets		
sodium oral soln 70				
mg/75 ml)				
CLOMID (clomiphene	Ovulation Induction	Please talk to your doctor	or pharmacist about other	
citrate tab 50 mg)		medication(s) available for	your condition.	
CLOMIPHENE	Ovulation Induction	Please talk to your doctor		
CITRATE (clomiphene		medication(s) available for		
citrate tab 50 mg)			,	
HYDROCODONE/	Pain/Inflammation	hydrocodone/		
IBUPROFEN	-	acetaminophen tablets		
(hydrocodone-ibuprofen				
tab 10-200 mg)				
U /				
	Health Insurance Mark	etplace (HIM) Revisions		
CLOMID - clomiphene	Infertility	Please talk to your doctor	or pharmacist about other	
citrate tab 50 mg	interency	medication(s) available for		
CLOMIPHENE -	Infertility	Please talk to your doctor	•	
clomiphene citrate tab	mortinty	medication(s) available for		
50 mg			your contailon.	
HYDROCODONE-	Pain	Please talk to your doctor	or pharmacist about other	
IBUPROFEN -		medication(s) available for		
hydrocodone/ibuprofen				
TAB 10-200 MG				
PHENELZINE -	Depression	Please talk to your doctor	or pharmacist about other	
phenelzine sulfate tab	Depression	medication(s) available for		
15 mg				
io ing	1			
Dalamaad	Porformance and Darfo	rmanco Soloct Drug List E	ivelucione	
	Anesthesia-	rmance Select Drug List E		
AKTEN (lidocaine hcl		Please talk to your doctor		
ophth gel 3.5%)	Ophthalmic	medication(s) available for		
ARTISS (fibrin sealant	Fibrin Sealant	Please talk to your doctor		
component solution)		medication(s) available for		
clopidogrel bisulfate tab	Acute Coronary	Please talk to your doctor		
300 mg (base	Syndrome	medication(s) available for	r your condition.	
equivalent)				

	· · · · · · · · · · · · · · · · · · ·	
PRADAXA (dabigatran	Thromboembolism/stro	There is a generic equivalent available. Please talk
etexilate mesylate cap	ke prophylaxis,	to your doctor or pharmacist about other
75 mg (etexilate base	DVT/PE Treatment,	medication(s) available for your condition.
equivalent))	DVT/PE Prophylaxis	
proparacaine hcl ophth	Anesthesia-	Please talk to your doctor or pharmacist about other
soln 0.5%	Ophthalmic	medication(s) available for your condition.
RADIOGARDASE	Cesium or Thalium	Please talk to your doctor or pharmacist about other
(prussian blue insoluble	Contamination	medication(s) available for your condition.
cap 0.5 gm)		
RECOTHROM	Pseudoaneurysms	Please talk to your doctor or pharmacist about other
(thrombin (recombinant)	,	medication(s) available for your condition.
for soln		
20000 unit, 5000 unit)		
RECOTHROM SPRAY	Pseudoaneurysms	Please talk to your doctor or pharmacist about other
KIT (thrombin		medication(s) available for your condition.
(recombinant) for soln		
20000 unit)		
RECOTHROM/SPRAY	Pseudoaneurysms	Please talk to your doctor or pharmacist about other
APPLICATOR KIT	F seddoaned ysms	medication(s) available for your condition.
(thrombin (recombinant) for soln		
20000 unit)		
THROMBIN-JMI	Pseudoaneurysms	Please talk to your doctor or pharmacist about other
DILUENT (thrombin for		medication(s) available for your condition.
soln		
20000 unit, 5000 unit)		
THROMBIN-JMI	Pseudoaneurysms	Please talk to your doctor or pharmacist about other
EPISTAXIS (thrombin		medication(s) available for your condition.
for soln kit		
5000 unit)		
THROMBIN-JMI	Pseudoaneurysms	Please talk to your doctor or pharmacist about other
SYRINGE SPRAY KIT		medication(s) available for your condition.
(thrombin for soln kit		
5000 unit,		
20000 unit)		
THROMBIN-JMI W/DIL	Pseudoaneurysms	Please talk to your doctor or pharmacist about other
SPRAY PUMP		medication(s) available for your condition.
ACTUATOR (thrombin		
for soln kit		
20000 unit)		
TISSEEL (fibrin sealant	Fibrin Sealant	Please talk to your doctor or pharmacist about other
component kit 2 ml, 4		medication(s) available for your condition.
ml,		
10 ml)		
TISSEEL (fibrin sealant	Fibrin Sealant	Please talk to your doctor or pharmacist about other
component solution)		medication(s) available for your condition.
VAGIFEM (estradiol	Vulvovaginal Atrophy	There is a generic equivalent available. Please talk
vaginal tab 10 mcg)		to your doctor or pharmacist about other
		medication(s) available for your condition.
VIIBRYD (vilazodone hcl	Depression	There is a generic equivalent available. Please talk
tab 10 mg, 20 mg, 40	Depression	to your doctor or pharmacist about other
mg)		medication(s) available for your condition.
VIMPAT (lacosamide	Seizures	There is a generic equivalent available. Please talk
	Geizures	
oral solution 10 mg/ml)		to your doctor or pharmacist about other medication(c) available for your condition
L		medication(s) available for your condition.

Dourf	armonae and Darfarmon	oo Soloot Drug Liot Evolus	lono	
amiodarone hcl tab	Arrhythmia	ce Select Drug List Exclus amiodarone tablet	sions	
400 mg	-	200 mg		
bromfenac sodium ophth	Inflammation-	diclofenac ophth soln		
soln 0.09% (base	Ophthalmic	0.1%, ketorolac		
equivalent) (once-daily)		tromethamine ophth soln 0.5%		
CETRAXAL	Infections- Otic		Ciprofloxacin otic soln	
(ciprofloxacin hcl otic			0.2%	
soln 0.2% (base				
equivalent))				
cholestyramine light	Hypercholesterolemia	cholestyramine light		
powder packets 4 gm cholestyramine powder	Hyperebelesterelemia	powder pak 4 gm cholestyramine powder		
packets 4 gm	Hypercholesterolemia	pak 4 gm		
ciclopirox olamine susp	Fungal Infections-	ciclopirox gel 0.77%,		
0.77% (base equivalent)	Topical	ciclopirox cream 0.77%		
diltiazem hcl coated	Angina, Hypertension,	diltiazem hcl coated		
beads tab er 24hr	Atrial Fibrillation/	beads capsule er 24 hr		
240 mg	Flutter	240 mg		
diltiazem hcl coated	Angina, Hypertension,	diltiazem hcl coated		
beads cap er 24hr	Atrial Fibrillation/	beads capsule er 24 hr		
180 mg, 360 mg	Flutter	180 mg		
diltiazem hcl coated	Angina, Hypertension, Atrial Fibrillation/	diltiazem hcl coated		
beads tab er 24hr 300 mg	Flutter	beads capsule er 24 hr 300 mg		
diltiazem hcl coated	Angina, Hypertension,	diltiazem hcl coated		
beads tab sr 24 hr	Atrial Fibrillation/	beads capsule er 24 hr		
180 mg, 360 mg	Flutter	180 mg		
diltiazem hcl coated	Angina, Hypertension,	diltiazem hcl coated		
beads tab sr 24hr	Atrial Fibrillation/	beads capsule er 24 hr		
240 mg	Flutter	240 mg		
diltiazem hcl coated	Angina, Hypertension,	diltiazem hcl coated		
beads tab sr 24 hr	Atrial Fibrillation/	beads capsule er 24 hr		
300 mg leucovorin calcium tab	Flutter High Dose	300 mg leucovorin calcium tablet		
10 mg	Methotrexate or	5 mg		
i e ing	Methotrexate Overdose			
megestrol acetate susp	Anorexia, Cachexia	megestrol acetate		
625 mg/5 ml		suspension 40 mg/ml		
oxycodone hcl cap 5 mg	Pain	oxycodone hcl tablet		
PREDNISONE	Inflammatory	5 mg	Prednisone solution	
INTENSOL (prednisone	Conditions		5 mg/5 ml	
conc 5 mg/ml)				
zolmitriptan orally	Migraine	zolmitriptan tablet,		
disintegrating tab 2.5		rizatriptan orally		
mg, 5 mg		disintegrating tablet		
Ba	lanced and Performance	Select Drug List Exclusion	ons	
NEXAVAR (sorafenib	Cancer	There is a generic equival		
tosylate tab 200 mg		to your doctor or pharmacist about other		
(base equivalent))		medication(s) available for your condition.		

PENNSAID (diclofenac	Inflammation- Topical	diclofenac sodium		
sodium soln 2%)		solution 1.5%		
PICATO (ingenol	Actinic Keratosis	Please talk to your doctor or pharmacist about other		
mebutate gel 0.015%, 0.05%)		medication(s) available for your condition.		
SPIRO PD (respiratory	Respiratory	Please talk to your doctor or pharmacist about other		
therapy supplies - devices)	supplies/devices	medication(s) available for your condition.		
THRESHOLD PEP	Respiratory	Please talk to your doctor or pharmacist about other		
(respiratory therapy supplies - devices)	supplies/devices	medication(s) available for your condition.		
	Balanced Drug	List Exclusions		
BUPROPION	Depression	Please talk to your doctor or pharmacist about other		
HYDROCHLORIDE E R (XL) (bupropion hcl tab er 24hr 450 mg)		medication(s) available for your condition.		
calcipotriene-	Plaque Psoriasis	Enstilar, Duobrii,		
betamethasone dipropionate oint 0.005-0.064%		Tazorac		
calcipotriene-	Plaque Psoriasis	Enstilar, Duobrii, Tazorac		
betamethasone dipropionate susp 0.005-0.064%		Tazorac		
EXFORGE HCT	Hypertension	There is a generic equivalent available. Please talk		
(amlodipine-valsartan- hydrochlorothiazide tab 10-160-12.5 mg, 10- 160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5- 160-25 mg)		to your doctor or pharmacist about other medication(s) available for your condition.		
FORFIVO XL (bupropion hcl tab er 24 hr 450 mg)	Depression	Please talk to your doctor or pharmacist about other medication(s) available for your condition.		
LIDOCAINE HCL JELLY (lidocaine hcl urethral/mucosal gel 2%)	Anesthesia- Urethral/ Mucosal	Please talk to your doctor or pharmacist about other medication(s) available for your condition.		
NALFON (fenoprofen	Pain/	There is a generic equivalent available. Please talk		
calcium cap 400 mg)	Inflammation	to your doctor or pharmacist about other medication(s) available for your condition.		
PENTASA (mesalamine	Ulcerative Colitis	There is a generic equivalent available. Please talk		
cap er 500 mg)		to your doctor or pharmacist about other medication(s) available for your condition.		
	Dorformanco Salaci			
diclofenac sodium soln	Inflammation- Topical	Drug List Exclusions diclofenac sodium		
2%		solution 1.5%		
penicillamine cap 250 mg	Cystinuria, Rheumatoid Arthritis, Wilson's Disease	penicillamine tablet 250 mg		
		etplace (HIM) Exclusions		
cholestyramine powder packets 4 gm	Hypercholesterolem	a Please talk to your doctor or pharmacist about other medication(s) available for your condition.		

		-
cholestyramine light powder packets 4 gm	Hypercholesterolemia	Please talk to your doctor or pharmacist about other medication(s) available for your condition.
ciclopirox olamine susp 0.77% (BASE EQUIV)	Fungal Skin Infections	Please talk to your doctor or pharmacist about other medication(s) available for your condition
diltiazem hcl coated beads tab ER 24HR 180mg, 240 mg	Hypertension/Angina	Please talk to your doctor or pharmacist about other medication(s) available for your condition
leucovorin calcium tabs 10 mg	Cancer	Please talk to your doctor or pharmacist about other medication(s) available for your condition
lidocaine hcl urethral/mucosal gel 2%	Anesthesia	Please talk to your doctor or pharmacist about other medication(s) available for your condition
NEXAVAR - sorafenib tosylate tab 200 mg (base equivalent)	Cancer	There is a generic equivalent available. Please talk to your doctor or pharmacist about other medication(s) available for your condition.
PRADAXA - dabigatran etexilate mesylate cap 75 mg (etexilate base equivalent)	Anticoagulation	There is a generic equivalent available. Please talk to your doctor or pharmacist about other medication(s) available for your condition.
proparacaine hcl ophth soln 0.5%	Anesthesia	Please talk to your doctor or pharmacist about other medication(s) available for your condition
VIIBRYD - vilazodone hcl tab 10 mg, 20 mg, 40 mg	Depression	There is a generic equivalent available. Please talk to your doctor or pharmacist about other medication(s) available for your condition.
zolmitriptan orally disintegrating tab 2.5 mg, 5 mg	Migraine	Please talk to your doctor or pharmacist about other medication(s) available for your condition.

¹Third-party brand names are the property of their respective owner.
²This list is not all inclusive. Other medicines may be available in this drug class.

Review Drug List Updates (Coverage Tier 1 to Tier 2 Changes) – As of Jan. 1, 2023

The generic drug changes listed below apply to members with a pharmacy benefit plan that includes a cost share differential for generic drugs (e.g. 5-tier or higher plan design with preferred generic and non-preferred generic lower tiers). The following drugs are moving from a preferred generic (tier 1) to a non-preferred generic (tier 2), effective Jan. 1, 2023. Members may pay more for these drugs.

Drug ¹	Drug Class/Condition Used For			
Multi-Tier Basic, Multi-Tier Enhanced and Performance Drug Lists				
amantadine hcl soln 50 mg/5 ml	Parkinson's Disease			
bisoprolol & hydrochlorothiazide tab	Hypertension			
2.5-6.25 mg, 10-6.25 mg				
carbidopa & levodopa tab 25-100 mg	Parkinson's Disease			
diltiazem hcl coated beads cap er 24hr 240 mg	Angina, Hypertension, Atrial Fibrillation/Flutter			
haloperidol tab 2 mg	Psychosis, Tourette Syndrome, Behavioral			
	Disorders			
hydrocodone-acetaminophen tab 10-325 mg	Pain			
hydroxyzine hcl syrup 10 mg/5 ml	Anxiety, Pruritus/Urticaria, Sedation,			
	Nausea/Vomiting			
olmesartan medoxomil-hydrochlorothiazide tab	Hypertension			
40-12.5 mg, 40-25 mg				
oxcarbazepine tab 150 mg	Seizures			
peg 3350-kcl-sod bicarb-nacl for soln 420 gm	Bowel Prep			
rizatriptan benzoate oral disintegrating tab	Migraine			
5 mg, 10 mg (base equivalent)				
thyroid tab 30 mg (1/2 grain)	Hypothyroidism			
valsartan-hydrochlorothiazide tab 80-12.5 mg	Hypertension			
	-Tier Enhanced Drug Lists			
stannous fluoride conc 0.63%	Dental Caries Prophylaxis			
Performance Drug List				
diltiazem hcl coated beads cap sr 24hr 240 mg	Angina, Hypertension, Atrial Fibrillation/Flutter			
nitrofurantoin monohydrate macrocrystalline cap Urinary Tract Infection 100 mg				

¹Third-party brand names are the property of their respective owner.

DISPENSING LIMIT CHANGES

The BCBSOK prescription drug benefit program includes coverage limits on certain medications and drug categories. Dispensing limits are based on U.S. Food and Drug Administration (FDA) approved dosage regimens and product labeling. **Changes by drug list are listed on the charts below.**

BCBSOK letters all members with a claim for a drug included in the Dispensing Limit Program, regardless of the prescribed dosage. This means members may receive a letter even though their prescribed dosage doesn't meet or exceed the dispensing limit.

Effective Jan. 1, 2023:

Drug Class and Medication(s) ¹	Dispensing Limit(s)			
Basic, Enhanced, Balanced, Performance, Performance Select and Health Insurance				
Marketplace (HIM) Drug Lists				
Alternative Dosage Form PAQL				
Fleqsuvy (baclofen) suspension 25 mg/ 5 mL	600 mL per 30 days			

Meloxicam suspension 7.5 mg/5 mL	300 mL per 30 days
Basic and Enha	anced Drug Lists
Vijoice PAQL	
Vijoice (alpelisib) Pak 250mg daily dose (200 mg	56 tablets per 28 days
& 50 mg)	
Vijoice (alpelisib) tab therapy Pack 50 mg,	28 tablets per 28 days
125 mg daily dose	

¹*Third-party brand names are the property of their respective owner.*

* Not all members may have been notified due to limited utilization.

UTILIZATION MANAGEMENT PROGRAM CHANGES

Members were notified about the PA standard program changes listed in the tables below.

Drug categories added to current pharmacy PA standard programs, effective Jan. 1, 2023:

Drug Category	Targeted Medication(s) ¹		
Basic, Basic Multi-tier, Enhanced and Enhanced Multi-tier Drug Lists			
GLP-1 (Glucagon-like peptide-1) Agonists GLP-1 (Glucagon-like peptide-1) Agonists GLP-1 (Glucagon-like peptide-1) Agonists GLP-1 (Glucagon-like peptide-1) Agonists GLP-1 (Glucagon-like peptide-1) Agonists (tirzepatide) injection, Ozempic (semaglutide) injection, Rybelsus (semaglutide) tablet, Trulicity (dulaglutide) injection, Victoza (liraglutide) injection			
Basic, Basic Multi-tier, Enhanced, Enhanced Multi-tier, Balanced, Performance, Performance Select and Health Insurance Marketplace (HIM) Drug Lists			
Alternative Dosage Form	Fleqsuvy (baclofen) supension 25 mg/ 5 mL*, Meloxicam suspension 7.5 mg/5 mL*		
Vtama VTAMA (tapinarof) 1% CREAM*			

Basic, Basic Multi-tier, Enhanced and Enhanced Multi-tier Drug Lists		
Vijoice	Vijoice (alpelisib) tablets	
¹ Third-party brand names are the property of their respective owner.		

* Not all members may have been notified due to limited utilization.

Other program changes being applied to pharmacy PA or Step Therapy (ST) standard programs include:

Effective Date	Program Name	Description of Change	Drug Lists	Program Type
Dec. 1, 2022	Vijoice	New PA program with target Vijoice (alpelisib) tablets*	Balanced, Performance, Performance Select, Health Insurance Marketplace (HIM) 2022, HIM 2023	Specialty PA
Jan. 1, 2023	GLP-1 (Glucagon- like peptide-1) Agonists	New PA program with various target drugs. This was a ST program that was retired, changed to a PA program and now apply to these additional drug lists.* New drug therapy starts will require PA review. Grandfathering is in place and members with a drug regimen history will not be impacted, except for those using the target drugs Adlyxin, Byetta and Mounjaro.	Balanced, Performance, Performance Select	PA
Jan. 1, 2023	Vtama	New PA program with target VTAMA (tapinarof) 1% CREAM* The target was part of the Therapeutics Alternatives PA program effective 10/1/22 and will now be a standalone program. Most members were lettered prior to that change.	Basic, Enhanced, HIM 2022, HIM 2023, Balanced, Performance, Performance Select	ΡΑ
Jan. 1, 2023	Camzyos	New PA program with target drug Camzyos. (mavacamten)*	Basic, Enhanced, HIM 2022, HIM 2023,	Specialty PA

			Balanced, Performance, Performance Select	
Jan. 1, 2023	Factor VIII and von Willebrand Factor PAQL	Name change (formerly Hemophilia VIII)	Basic, Enhanced, HIM 2022, HIM 2023, Balanced, Performance, Performance Select	Specialty PA
Jan. 1, 2023	Ophthalmic Prostaglandins	Name change (formerly Glaucoma)	Basic, Enhanced, HIM 2022, HIM 2023	ST
Jan. 1, 2023	Atypical Antipsychotics – Extended Maintenance Agents	ST program retiring	Basic, Enhanced, HIM 2022, HIM 2023	ST

¹Third-party brand names are the property of their respective owner. * Not all members may have been notified due to limited utilization.

Per our usual process of member notification prior to implementation, targeted mailings were sent to members affected by drug list revisions and/or exclusions and prior authorization program changes. For the most up-to-date drug list and list of drug dispensing limits, visit the Pharmacy Program section of our Provider website.

If your patients have any questions about their pharmacy benefits, please advise them to contact the number on their member ID card. Members may also visit *bcbsok.com* and log in to Blue Access for MembersSM (BAMSM) or MyPrime.com for a variety of online resources.

Change in Benefit Coverage for Select High-Cost Products

Several high-cost products with available lower cost alternatives will be excluded on the pharmacy benefit for select drug lists. This change impacts BCBSOK members who have prescription drug benefits administered by Prime Therapeutics. This change is part of an ongoing effort to make sure our members and employer groups have access to safe, cost-effective medications.

Please note: Members were not notified of this change because there is no utilization or the pharmacist can easily fill a member's prescription with the equivalent without needing a new prescription from the doctor. The following drugs are excluded on select drug lists:

Product(s) No Longer Covered ^{1*}	Condition Used For	Covered Alternative(s) ^{1,2}
RELAFEN DS TAB 1000MG	INFLAMMATION AND PAIN	RELAFEN 500 MG OR 750 MG TABS
FLUTICASONE FUROATE- VILANTEROL ELLIPTA INH 100 MCG-25 MCG, 200 MCG- 25 MCG	ASTHMA	BREO ELLIPTA
FLUTICASONE PROPIONATE HFA AER 44 MCG, 110 MCG, 220 MCG	ASTHMA	FLOVENT HFA
INSULIN GLARGINE (WINTHROP)	DIABETES	INSULIN GLARGINE-YFGN, SEMGLEE-YFGN
INSULIN GLARGINE SOLOSTAR (WINTHROP)	DIABETES	INSULIN GLARGINE-YFGN, SEMGLEE-YFGN

1 All brand names are the property of their respective owners.

2 This list is not all-inclusive. Other products may be available. * This chart applies to members on the Basic, Multi-Tier Basic, Enhanced and Multi-Tier Enhanced Drug Lists.

Implementation of New to Market Clinical Review Program for Select Prescription Drug Lists

Reminder: A New to Market program applies to FDA-approved drugs launched into the market on or after Oct. 1, 2022. This replaces a similar program that was offered on our Basic and Enhanced prescription drug lists for select BCBSOK commercial plan members.

Program details: The program implements coverage exception clinical evaluation processes on new-tomarket drug products until coverage evaluation decisions can be determined. Once the final clinical evaluation criteria is implemented, members that started drug therapy and have approval are not disrupted. Oral oncology and anti-retroviral drugs are not included.

Please call the number on the member's ID card to start any coverage exception review process, to verify coverage, or for further assistance or clarification on your patient's benefits.

New Proactive Utilization Management Approval Renewal Program: SmartRenew™

Reminder: Certain prescription drugs require utilization management (UM) program approval year over year. This can include prior authorization approval, step therapy exception requests and dispensing/quantity limits override requests. To help avoid you having to submit the request each year for your patients, a new proactive UM renewal program, **SmartRenew**[™], was launched on Oct. 1, 2022.

This program helps save both you and your patient time and effort in needing to submit a new request, reduces frustration and potential coverage delays from not having an updated approval and provides a better overall experience.

Program Details:

- Applies to a pre-determined and regularly updated list of prescription drugs covered under the member's BCBSOK pharmacy benefit. These drugs are typically used for maintenance and have a high reapproval rate.
- The member and you do not need to do anything for drugs included in the program. Authorization approvals are automatically extended for 12 months, based on set program criteria. Members will need to meet program criteria, such as having:
 - o a prior approval for a duration of at least six to 12 months,
 - o a current prescription for an included drug product,
 - claims history within the past 180 days and
 - o no change in coverage for their medication.
- Members are sent a notification of the drug's automatic approval confirmation and new expiration date. Identification of members will be ongoing. Letters will be sent at least 60 days prior to the original approval expiration date.

Please call the number on the member's ID card to for further assistance or clarification on your patient's benefits.

Split Fill Program Category Expansion

Starting on Jan. 1, 2023, the Split Fill Program will be expanded to include additional categories beyond oral oncology medications, such as multiple sclerosis and iron toxicity.

Reminder:

BCBSOK offers its members and groups a Split Fill Program to reduce waste and help avoid costs of select specialty medications that may go unused. Members new to therapy (or have not had claims history within the past 120 days for the drug) are provided partial, or "split," prescription fills for up to three months.

The Split Fill Program applies to a specific list of drugs known to have early discontinuation or dose modification. You can view the current list of drugs and find more information on the <u>Split Fill Program</u> on our Provider website.

Please call the number on the member's ID card to verify coverage, or for further assistance or clarification on your patient's benefits.

Prime Therapeutics LLC is a pharmacy benefit management company. BCBSOK contracts with Prime to provide pharmacy benefit management and related other services. BCBSOK, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime. MyPrime.com is an online resource offered by Prime Therapeutics.

The information mentioned here is for informational purposes only and is not a substitute for the independent medical judgment of a physician. Physicians are to exercise their own medical judgment. Pharmacy benefits and limits are subject to the terms set forth in the member's certificate of coverage which may vary from the limits set forth above. The listing of any particular drug or classification of drugs is not a guarantee of benefits. Members should refer to their certificate of coverage for more details, including benefits, limitations and exclusions. Regardless of benefits, the final decision about any medication is between the member and their health care provider.